AI-Designed Vaccine Enters Human Trials as Researchers Pursue Broad Virus Protection
Researchers at the University of Cambridge have completed the first human trials of a vaccine whose key component was designed entirely by artificial intelligence. The vaccine targets all known coronaviruses, including Covid variants and animal viruses with pandemic potential.
The trial involved 39 people and assessed safety. A second study with around 200 participants will measure how effectively the vaccine trains the immune system.
How the AI Design Works
Traditional vaccines are built from current virus strains. The Cambridge team took a different approach: they fed an AI system genetic codes from multiple coronaviruses collected through surveillance programs.
The AI then designed a "super-antigen" - the component that trains the immune system to recognize and attack viruses. This antigen was engineered to protect against the entire coronavirus family, even as viruses mutate or jump from animals to humans.
"What we're trying to do is get ahead of the curve," said Prof Jonathan Heeney from Cambridge. "So far ahead they could protect against new outbreaks or pandemics."
Early Results and Next Steps
The Journal of Infection reported the vaccine generated a "modest" immune response in trial participants. Despite the measured results, researchers and independent experts see potential.
Prof Saul Faust, who conducted some trials at the University of Southampton, said the AI design "definitely has potential" and was "really exciting," particularly for vaccines targeting rapidly changing viruses.
Cambridge researchers are now testing animal models for universal seasonal flu vaccines that would not require yearly updates, and an H5N1 bird flu vaccine. They are also exploring a vaccine for viral haemorrhagic fevers, including Ebola species.
The Broader Significance
Prof Andy Pollard from the Oxford Vaccine Group, who was not involved in the study, said the approach had generated "fascinating data" in animal research. He cautioned that human trials remain the critical test, since human immune systems differ from laboratory models due to years of prior infections.
Pollard said AI would be a "game changer" for vaccine research, potentially predicting immune responses and accelerating development timelines.
The work represents a shift in pandemic preparedness. Rather than designing vaccines after a virus emerges, researchers can now use AI to anticipate threats from known viral families.
For professionals working in science and research, this demonstrates how AI for Science & Research is moving from theoretical applications to clinical validation. The methodology also has implications across AI for Healthcare more broadly.
Your membership also unlocks:
